Pegteograstim may be effective for reducing chemotherapy-induced neutropenia
the ONA take:
Pegteograstim is as effective as pegfilgrastim in reducing chemotherapy-induced neutropenia in patients with breast cancer undergoing myelosuppressive chemotherapy, a new study published online ahead of print in the journal Supportive Care in Cancer has shown.
For the phase 2/3 study, researchers sought to evaluate the efficacy and safety of pegteograstim, a new formulation of pegylated granulocyte-colony-stimulating factor (G-CSF), compared with pegfilgrastim in preventing febrile neutropenia.
In the phase 3 portion, researchers enrolled 117 patients with breast cancer who were undergoing treatment with docetaxel plus doxorubicin or docetaxel plus doxorubicin and cyclophosphamide.
Patients were randomly assigned to receive pegteofilgrastim 6.0 mg subcutaneously on day 2 of chemotherapy or pegfilgrastim 6.0 mg subcutaneously.
Results showed that the efficacy of pegteograstim was noninferior to that of pegfilgrastim in the duration of grade 4 neutropenia during cycle 1 of chemotherapy.
Furthermore, the time to absolute neutrophil count recovery was significantly shorter with pegteograstim compared with pegfilgrastim.
In regard to safety, treatment-related adverse events did not differ significantly between the two treatment arms.
Pegteograstim is as effective as pegfilgrastim in reducing chemotherapy-induced neutropenia in patients with breast cancer.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma
- Apalutamide Prolongs Time to Metastasis in Castration-resistant Prostate Cancer
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|